Two-Year trial tests Long-Term safety of gut hormone treatment

NCT ID NCT07228403

ENROLLING_BY_INVITATION Disease control Sponsor: Zealand Pharma Source: ClinicalTrials.gov ↗

Summary

This study follows patients with short bowel syndrome for two years to see if continuing treatment with glepaglutide remains safe and effective. It includes 35 adults who were already receiving this medication in previous trials. The main goal is to monitor side effects and see if the treatment continues to help reduce the need for intravenous nutrition support.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SHORT BOWEL SYNDROME (SBS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AP-HP - Hôpital Beaujon

    Clichy, Hauts-de-Seine, 92118, France

  • Asklepios Klinik St. Georg

    Hamburg, 20099, Germany

  • Charité - Universitätsmedizin Berlin

    Berlin, State of Berlin, 10117, Germany

  • Cleveland Clinic-9500 Euclid Ave

    Cleveland, Ohio, 44195-0001, United States

  • LHSC - University Hospital

    London, Ontario, N6A 4V2, Canada

  • Lied Transplant Center at Nebraska Medical Center

    Omaha, Nebraska, 68105, United States

  • Mayo Clinic - PPDS

    Rochester, Minnesota, 55905-0001, United States

  • Samodzielny Publiczny Szpitala Kliniczny im. Prof. Witolda Orlowskiego CMKP

    Warsaw, Masovian Voivodeship, 00-416, Poland

  • St Mark's Hospital (Central Middlesex Hospital)

    Ealing, NW10 7NS, United Kingdom

  • Szpital Skawina sp. z o.o. im. Stanley Dudricka

    Skawina, Lesser Poland Voivodeship, 32-050, Poland

  • UZ Leuven - PPDS

    Leuven, 3000, Belgium

  • Universitätsklinikum Bonn

    Bonn, North Rhine-Westphalia, 53127, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt am Main, Hesse, 60590, Germany

  • Universitätsmedizin Rostock

    Rostock, Mecklenburg-Vorpommern, 18057, Germany

  • Vanderbilt University Medical Center-Tennesse-1211 21st Ave S

    Nashville, Tennessee, 37212-2700, United States

  • Wojewódzki Szpital Specjalistycznyo im. M. Pirogowa w Lodzi

    Lodz, 90-531, Poland

Conditions

Explore the condition pages connected to this study.